A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo in participants with generalized myasthenia gravis (gMG).
Inclusion Criteria:
Exclusion Criteria:
CABA, C1199ABA, Argentina
CABA, C1221ADC, Argentina
Ciudad Autonoma Bs As, C1280AEB, Argentina
Wuhan, 430030, China
Chiba-shi, Chiba, 260-8677, Japan
Hanamaki, Iwate, 025-0082, Japan
Hokkaido, 060-8543, Japan
Hokkaido, 063-0005, Japan
Narita, Chiba, 286-0124, Japan
Gda?sk, 80-952, Poland
Gyeongsangnam-do, 50612, South Korea